Organization (Industry)
Santen (France)
ClinicalTrials.gov lists Santen (France) as lead sponsor of 87 trials. It has 36 active development programs and 14 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo RicHard-59, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Santen (France): 87 lead-sponsored trials and 6 legal-entity registrations.
Disease areas (28)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Glaucoma | 38 |
| Glaucoma, Open-Angle | 32 |
| Dry Eye Syndromes | 18 |
| Macular Degeneration | 7 |
| Conjunctivitis, Allergic | 4 |
Showing 5 of 28 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 6 |
| 2021 | 5 |
| 2020 | 2 |
| 2019 | 9 |
| 2018 | 5 |
| 2017 | 7 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (36)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Co-Latanoprost | Glaucoma | Phase 3 | 10 |
| Co-Latanoprost | Glaucoma, Open-Angle | Phase 3 | 9 |
| STN1013800 ophthalmic solution | Blepharoptosis | Phase 3 | 2 |
| DE-117B Eye Drops | Glaucoma | Phase 3 | 1 |
| STN1013800 ophthalmic solution Liquid Base, without STN1013800 | Blepharoptosis | Phase 3 | 1 |
Showing 5 of 36 active programs.
Approved assets (14)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| 0.5% moxifloxacin hydrochloride ophthalmic solution | 3 |
| 1.5% levofloxacin ophthalmic solution | 3 |
| 1mg/mL ciclosporin | 1 |
| 0.3% gatifloxacin ophthalmic solution | 1 |
| Co-Latanoprost | 10 |
Showing 5 of 14 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 60% hit target (n=25) | 46% on time (n=24) |
Journals published in (45)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of cataract and refractive surgery | 12 |
| Clinical ophthalmology (Auckland, N.Z.) | 10 |
| Archives of ophthalmology (Chicago, Ill. : 1960) | 5 |
| Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics | 5 |
| Ophthalmology | 4 |
Showing 5 of 45 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 321 | 29 | 2025-12-30 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 12 | 2026-02-09 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Santen Pharmaceuticals Co. Ltd. | Hakui-Gun, JP | EMA | |
| Santen Pharmaceuticals Co. Ltd. | Inukami Gun, JP | EMA |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| European Society of Cataract and Refractive Surgeons | Co sponsors trial with | 1 |
| University of London | Co sponsors trial with | 1 |
| Ludwig-Maximilians-Universität München | Co sponsors trial with | 1 |
| The Cleveland Clinic | Co sponsors trial with | 1 |
| ActualEyes, Inc. | Co sponsors trial with | 1 |
Latest dated events (431)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-09 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-19 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-07-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 431 events.
Biomarker capability evidence (39)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AATF | Trial collaborator | Named in trial inclusion criteria |
| AATF | Trial sponsor | Named in trial inclusion criteria |
| AATF | Trial collaborator | Named in trial inclusion criteria |
| AATF | Trial sponsor | Named in trial inclusion criteria |
| ETV5 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 39 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.